|
Indian Pediatr 2011;48:
703-707 |
 |
Profile of HIV Infected Children from Delhi
and Their Response to Antiretroviral Treatment |
Sunil Gomber, Jaya Shankar Kaushik, *Jagdish Chandra and Rahul Anand
From Department of Pediatrics, University College of
Medical Sciences and Guru Teg Bahadur Hospital; and *Kalawati Saran
Children Hospital; Delhi, India.
Correspondence to: Dr Sunil Gomber, 7/10, Delhi
Government Officers’ flats, Probyn Road, Mall Road, Delhi 110 054. Email:
[email protected]
Received: April 28, 2010;
Initial review: May 07, 2010;
Accepted: August 23, 2010.
Published online: 2010, November 30.
PII:S097475591000353-1
|
Objectives: (i) To study the clinical and
immunological profile of HIV infected children attending the ART centre; (ii)
To correlate CD4 count with clinical staging at diagnosis; and, iii)
To study the clinical and immunological response to antiretroviral
treatment.
Setting: Antiretroviral therapy (ART) centres of
two tertiary care hospitals of Delhi.
Patients: 100 children attending the centres
between December 2008 to June 2009.
Methods: The clinical features, immunological
profile (CD4 count) and response to ART were recorded in a structured
proforma.
Design: Prospective follow-up.
Results: Average age of enrolled children was 6.24
y (range 1-14 years) and mode of transmission was parent to child in 92%.
Most common clinical presentation was fever (83%), cough (50.8%) and
diarrhea (38.9%). Tuberculosis was the most common opportunistic infection
seen in 11% of children. 59% of enrolled children were malnourished.
Antiretroviral treatment (ART) was initiated in 33 children. Children who
were initiated on ART had a significant improvement in both clinical and
immunological staging at the 6 months follow up. Immunological response
(rise in CD4 count) to ART was better in children with lesser degree of
immunosuppression. The measure of agreement between the clinical and
immunological stage at presentation was poor.
Conclusions: Baseline CD4 counts rather than
clinical staging can be a primary determinant for initiation of
antiretroviral treatment in HIV infected children.
Key words: Anti-retroviral treatment, CD4 count, Clinical stage,
Outcome, Treatment.
|
Human immunodeficiency virus (HIV) infection is a growing concern in
pediatric population and large number of children are registered and
treated at Antiretroviral treatment (ART) centres across the country [1].
Despite the magnitude of illness, there is a lack of studies describing
the correlation of clinical staging and immunological staging (CD4 count)
in HIV infected children. We report the clinical and immunological profile
of children attending ART clinics of two tertiary care centers of Delhi,
along with their response to antiretroviral treatment.
Methods
This was a prospective study conducted in ART clinics
of two tertiary care hospitals of Delhi over a period of six months from
December 2008 to June 2009. A sample size of 96 subjects (rounded to 100)
was obtained with 95% confidence interval and 10% absolute precision (2
sided) in prevalence of diarrhea in HIV infected children, which was
approximately 55% in a previous study [2]. The sample size was estimated
using Power analysis and sample size (PASS) software. A total of 100
children aged less than 18 years were enrolled in the study (50 each from
two study centres). A clearance was obtained from institutional ethical
committee. The study protocol was fully explained to parents/guardian and
written informed consent was obtained.
The diagnosis of HIV was confirmed by ELISA using two
different antigens (COMB HIV, TRI DOT) in children more than 18 months. In
children less than 18 months, diagnosis was confirmed by positive DNA PCR
(repeated twice with cessation of breastfeeding for minimum of six weeks).
Demographic profile, clinical presentation and mode of transmission of
enrolled children were recorded in a predesigned proforma. Anthropometric
assessment was done and WHO classification for malnutrition was adopted to
classify children into stunted, wasted and both stunted and wasted [3].
Children were categorized by their presenting complaints into clinical
staging as per WHO clinical classification for HIV infected children [4].
Opportunistic infections were screened using Mantoux test, chest skiagram,
microscopic examination of sputum, urine and stool. It also included the
examination of skin and oral mucosa with scrapings for potassium hydroxide
(KOH) mount preparation [4]. Baseline value of hemogram, serum bilirubin,
serum aminotransferase, blood urea and serum creatinine was obtained in
all children. Other investigations were planned as deemed necessary. CD4
count was estimated by FACS (fluorescent activated cell sorter) method
(Becton-Dickinson). Immunological assessment was done in terms of CD4
counts as per WHO classification [4].
Children were started on ART as per National AIDS
Control Organisation (NACO) guidelines [5]. Combination of two nucleoside
reverse transcriptase inhibitor (NRTI) and one non-nucleoside reverse
transcriptase inhibitor (NNRTI) was started. Children were monitored
clinically weekly or monthly, depending on the clinical presentation.
Children were observed for clinical improvement or detoriation, compliance
with medications and for any adverse effects of ART. CD4 counts were
repeated every 6 months.
Data were analyzed using SPSS version 17.0. All
quantitative variables including age, weight, height and body mass index
were compared by unpaired t-test; categorical variables like sex, mode of
delivery and mode of transmission were compared by Chi-square test or
Fisher’s exact test. Variables like clinical staging, immunological
staging and CD4 counts which were measured repeatedly (at presentation and
at follow up) were analysed with repeated measure ANOVA followed by Tukey
procedure at 5% level of significance to allow for multiple comparisons.
To find the agreement between clinical staging and immunological staging,
kappa statistic was applied. P<0.05 was considered as significant.
Results
All the 100 children were brought for follow up till 6
months. Their mean age of presentation was 6.24+2.93 (range 1-14)
years, 33% were below 5 years and there were 70 males. 41 children were
asymptomatic at diagnosis, of the rest only two required hospitalization
for non-resolving pneumonia.
Nutritional status was normal in 41 children. Among the
rest 59 children, 13 (22%) were wasted, 23 (38.9%) were stunted, and 23
(38.9%) were both wasted and stunted. Severe wasting and severe stunting
were present in 12/59 (20.3%) and 8/59 (13.5%) children. Mean body mass
index in children more than 5 years was 13.92.
The possible mode of transmission was parent to child
in 90 children, blood transfusion in 4 children, unsafe injection
practices in 1 child and in 5 children, the mode of transmission was not
clear. Majority of children were born by vaginal delivery (93%) with only
2% born by cesarean section. Five children were orphans brought to our
centre by local non-governmental organisation and their birth and family
details were not available.
Common clinical symptoms at diagnosis were fever (83%),
cough (50.8%) and diarrhea (38.9%). Skin manifestations were observed in
6.7% of children and included pyoderma, extensive warts and molluscum
contagiosum. Mucosal presentations include oral ulcerations (44.1%) and
candidiasis (14.7%). Tuberculosis was the most common opportunistic
infection diagnosed in 11% of children. Parotitis and acute suppurative
otitis media were seen in one child each.
Age wise distribution of baseline mean (SD) CD4 count
was 961.6 (535.1) [1-5 years]; 659.4 (544.7) [5-9 years]; 603.3 (500.1)
[9-13years]; 422 (226.3) [above 13 years]. Baseline CD4 count was
significantly higher in children less than 5 years (P=0.003).
Table I depicts the relation between clinical staging and
immunological staging at presentation. Agreement between the clinical and
immunological stage at presentation was poor ( k
43.6%).
Table I
Clinical and Immunological Staging at Presentation
|
Immune stage 1 |
Immune stage 2 |
Immune stage 3 |
Immune stage 4 |
Total |
WHO stage 1 |
47 |
16 |
2 |
1 |
66 |
WHO stage 2 |
0 |
3 |
1 |
2 |
6 |
WHO stage 3 |
0 |
7 |
9 |
6 |
22 |
WHO stage 4 |
0 |
1 |
0 |
5 |
6 |
Total |
47 |
27 |
12 |
14 |
100 |
kappa 43.6% form agreement between WHO staging and immune staging
at presentation. |
Thirty three children were initiated on ART. Compliance
with medications was good and none developed any adverse reaction to ART.
Of these, 28 were started on ART based on clinical staging (clinical stage
III, 22 and stage IV, 6) and 5 children were started ART based on
immunological criteria (CD4 guided). 22 children were started on
combination of lamivudine, stavudine and nevirapine; seven children
started on combination of lamivudine, zidovudine and efavirenz; and three
children on combination of lamivudine, stavudine and efavirenz. Efavirenz
based therapy was started in children diagnosed with tuberculosis and they
were reverted back to nevirapine based therapy after completion of
antitubercular treatment. ART combination was based on availability of ART
in the centre. 70% [23] of children who were initiated on ART were
malnourished (stunted, wasted, or both). Mean (SD) hemoglobin level in
children on zidovudine based ART was 8.75 (1.28) g/dL and those on
stavudine based ART was 8.6 (2.68) g/dL.
Children who were initiated on ART had a significant
improvement in both clinical and immunological staging at the 6 months
follow up (P=0.001). There was a significant rise in CD4 count at
the six month follow up in these children. However, the rise in CD4 count
was not related to stage of clinical presentation at diagnosis (Table
II). Mean (SD) increase in CD4 count for children on ART was 317.4
(155.1) per cu mm. In children who were not initiated on ART (n=67),
there was no change in either clinical or immunological staging at the
follow up. The mean (SD) decline in CD4 count in this group was 106.4
(333.8) per cu mm (P=0.015).
Table II
Mean (SD) CD4 Counts at Presentation and Follow up
Presentation |
Children on ART (n=33) |
Children not on ART (n=67) |
Staging |
No. |
CD4 pre |
CD4 FU |
Change CD4 |
No. |
CD4 pre |
CD4 FU |
Change CD4 |
|
|
Mean (SD) |
Mean (SD) |
Mean(SD) |
|
Mean (SD) |
Mean (SD) |
Mean (SD) |
WHO stage |
Stage I |
1 |
287.8(120.5) |
597.8 (213.8) |
310 (151.6) |
65 |
979.9 (528.0) |
875.9 (528.0) |
-108.1 (338.6) |
Stage II |
4 |
287.8 (120.5) |
597.8 (213.8) |
310 (151.6) |
2 |
407 (69.3) |
354. (107.5) |
-53 (38.2) |
Stage III |
22 |
292.3 (122.8) |
578.8 (22.5) |
286.5 (136.7) |
0 |
NA |
NA |
NA |
Stage IV |
6 |
258.2 (227.8) |
695.0 (366.1) |
436.8 (188.8) |
0 |
NA |
NA |
NA |
Immunological stage |
Stage I |
0 |
NA |
NA |
NA |
47 |
1141.6 (529.6) |
950.7 (443.9) |
- 194 (343.3) |
Stage II |
9 |
391.9 (41.5) |
749.3 (163.9) |
357.4(143.4) |
18 |
542.3 (164.2) |
659.5 (275.6) |
125 (210.3) |
Stage III |
10 |
305.5 (82.5) |
550.4 (197.7) |
244.9 (126.8) |
2 |
544.0 (296.9) |
545(91.9) |
1.0 (205.5) |
Stage IV |
14 |
202.6 (167.0) |
546.1 (295.2) |
343.5 (171.7) |
0 |
NA |
NA |
NA |
Total |
33 |
285.4 (141.4) |
602.8 (247.8) |
317.4 (155.1) |
67 |
962.8 (520.2) |
860.4 (420.6) |
-106.4 (333.6) |
Significance: On ART - WHO staging (pre and FU): Within group P = 0.00; between group P =0.9; Immune staging
(pre and FU): - Within group P =0.00; between group P = 0.04; Not WHO staging (pre and FU):- Within group = 0.52,
between group 0.09; Immune staging (pre and FU): Within subject P = 0.76, between subjects P <0.001.
|
In children on ART, CD4 count at the follow up varied
significantly with the immunological stage of presentation (P=0.04).
Rise in CD4 count was inversely related to the degree of immune
suppression at onset. Children with better baseline CD4 count had a better
rise in CD4 count in response to ART. However, no difference was observed
among the clinical stages in relation to CD4 counts at presentation and at
follow up (Table II).
Discussion
Clinical profile of HIV infected children in our ART
centre was similar to those reported earlier [6]. However, in our study,
41% of children were asymptomatic with normal nutritional status. This is
in contrast to another study from India which revealed prevalence of
underweight, stunting and wasting of 63%, 58% and 16%, respectively [7].
This could be attributed to early diagnosis of illness in the asymptomatic
stage as large number of children are diagnosed positive because of their
parents’ HIV status [8]. Moreover, these children are also supported by
non governmental organisations which provide good nutritional
rehabilitation to them. However, more studies are required to determine
whether nutritional rehabilitation early in the course of illness would
improve the nutritional status of HIV infected children.
Clinical and immunological improvement to
antiretroviral in our study is similar to previous Indian studies [9,10].
However, we observed that improvement in CD4 count was better among
children with higher baseline CD4 count i.e. lesser degree of
immunosupression. Similar observations have been reported in adults by
Lawn, et al. [11], but seldom reported in children. This could be
attributed to overwhelming opportunistic infections observed with higher
degrees of immunosupression. Hence earlier detection and higher baseline
CD4 count might improve the outcome of antiretroviral treatment.
WHO has laid down guidelines for initiation of ART
based on the clinical staging (stage III/IV) and immunological staging
i.e. CD4 counts in stage 1 and II [5]. In view of poor measure of
agreement observed between the clinical and immunological staging at
presentation in our study, we emphasise the need for CD4 count rather than
clinical staging in guiding the initiation of antiretroviral treatment in
children. Moreover, improvement in CD4 counts was better among children
with higher baseline CD4 count i.e. lesser degree of immunosupression.
Hence, earlier detection and higher baseline CD4 count might improve the
outcome of antiretroviral treatment. Moreover, WHO clinical staging was
designed for use in resource limited settings where access to laboratories
is poor. Reliability of clinical staging for initiation of ART is hence
debatable.
The limitations of our study include small sample size
and the short study period. Provision of free-of-cost medicines, efforts
of large number of social organisation, and achievement of universal
treatment access has indeed resulted in excellent compliance and scheduled
regular follow up visit [12]. Availability of CD4 count assay is limited
to tertiary care hospitals and cheaper and newer methods for estimation of
CD4 count are being developed [13]. CD4 guided initiation of ART
irrespective of clinical staging might ensure full benefits of ART and
might delay the progression of disease to advanced stage.
Our study concludes that baseline CD4 counts rather
than clinical staging can be a primary determinant for initiation of
antiretroviral treatment in HIV infected children. However, we recommend
further studies with longer follow up and larger sample size.
Contributors: SG, RA, JC, JSK were involved in
diagnosis and management of the cases. JSK drafted the paper and searched
the literature. SG and JC provided critical comments. All authors approved
the final manuscript.
Funding: None.
Competing interests: None stated.
What is Already Known?
• HIV infection is a growing concern in Indian
children.
What This Study Adds?
• Baseline CD4 counts should be used as a
primary determinant for initiating antiretroviral therapy in HIV
infected children.
|
References
1. Department of AIDS Control, Ministry of Family
Welfare, Government of India. Annual Report 2008-2009. Available from:
http://nacoonline.org/upload/Publication/Annual_ Report_NACO_2008-09.pdf.
Accessed on 27 February, 2010.
2. Asnake S, Amsalu S. Clinical manifestations of
HIV/AIDS in children in Northwest Ethiopia. Ethiop J Health Dev.
2005;19:24-8.
3. Shah D, Gupta P, Ghai OP. Nutrition and health.
In: Gupta P, Ghai OP. Eds. Textbook of Preventive and Social Medicine.
2nd ed. New Delhi: CBS Publisher and Distributors; 2004. p.100-54.
4. Shah N. Clinical diagnosis of pediatric HIV. In:
Shah I, Shah NK, Manglani M. eds. IAP Speciality Series on Pediatric HIV.
1st ed. Mumbai: Indian Academy of Pediatrics; 2007. p. 21-9.
5. Shah I. Antiretroviral therapy. In: IAP
Speciality Series on Pediatric HIV. Shah I, Shah NK, Manglani M editors.
1st ed. Mumbai: Indian Academy of Pediatrics; 2007. p. 63-9.
6. Agarwal D, Chakravarty J, Sundar S, Gupta V, Bhatia
BD. Correlation between clinical features and degree of immunosuppression
in HIV infected children. Indian Pediatr. 2008;45:140-3.
7. Padmapriyadarshini C, Poornagangadevi N,
Chadrasekaran K, Subramanian S, Thiruvalluvan C, Bhavani PK, et al.
Prevelance of underweight, stunting, and wasting among children infected
with human immunodeficiency virus in south India. Int J Pediatr. 2009;
2009:837627.
8. Hamadache D. HIV testing guidelines for children of
confirmed or suspected HIV positive parents. Available from http://www.chiva.org.uk/health/guidelines/hiv-testing.
Accessed on 27 February, 2010.
9. Natu SA, Daga SR. Antiretroviral therapy in
children: Indian experience. Indian Pediatr. 2007;44:339-43.
10. Shah I. Correlation of CD4 count, CD4% and HIV
viral load with clinical manifestations of HIV in infected Indian
children. Ann Trop Paediatr. 2006;26:115-9.
11. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count
recovery among HIV-infected patients with very advanced immunodeficiency
commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis.
2006;6:59.
12. Universal Access to AIDS Treatment: Targets and
Challenges. Available from http://www.avert.org/universal-access.htm.
Accessed on 27 February, 2010.
13. Pattanapanyasat K, Thakar MR. CD4+ T cell count as
a tool to monitor HIV progression and anti retroviral therapy. Ind J Med
Res. 2005;121:539-49.
|
|
 |
|